Johnson & Johnson (JNJ) said Thursday it would update a rationing program for the cancer drug Doxil to maximize the remaining supply and provide additional treatment cycles to patients already enrolled in the allocation program. A shortage of Doxil, which treats ovarian and other cancers, emerged last year after J&J’s contract manufacturer, Boehringer Ingelheim GmbH’s Ben Venue Laboratories unit, experienced production problems. Ben Venue halted production at its Ohio plant in November to address regulatory concerns about contamination; it expects to resume production in late 2012.
